Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

This profile has not been claimed by the company. See reviews below to learn more or submit your own review. How do I know I can trust these reviews about Armstrong Flooring? How do I know I can trust ...

DNA Ginkgo Bioworks Holdings, Inc.

Donald Trump's operation in Venezuela was a wild success, writes Armstrong Williams. Now comes the hard part of what comes next.

Rockwool A/S Series A-0.16% kr.47.39B Rockwool A/S Series B-0.47% kr.47.39B Go to the homepage.